Company intelligence / Profile preview

Toronto Memory Program

Toronto, Ontario, Canadatorontomemoryprogram.com ↗

Ownership: Private
Development stage: Commercial

Overview

Toronto Memory Program has contributed to over one hundred drug treatment studies in Alzheimer’s and related disorders since its founding in 1996. It has been involved with pivotal global clinical trials that have advanced new therapies for neurodegenerative diseases. The clinic also offers access to innovative diagnostics such as C2N Diagnostics’ PrecivityAD2 blood test for Alzheimer's diagnosis—the first Canadian site to do so—demonstrating leadership in both research and patient care

Therapeutic areas: Neurology
Modalities: Small moleculeBiologicDeviceNon-pharmacological therapy
Industry: Contract Research Organization

Partnerships

C2N Diagnostics (for PrecivityAD2 blood test)Multiple pharmaceutical sponsors for clinical trial execution.

Beyond the preview

Go deeper on Toronto Memory Program.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toronto Memory Program.

Explore the full profile